CXCL10 and chronic obstructive pulmonary disease: In the same study, mice treated with CXCL10 neutralizing antibody did not develop COPD features (weight loss; reduction of lung function, increased levels of IL-6, and CCL2 in BALF and lung homogenate) as compared to cigarette smoke-exposed mice.